

# Association of Concussion Symptoms With Testosterone Levels and Erectile Dysfunction in Former Professional US-Style Football Players

Rachel Grashow, PhD, MS; Marc G. Weisskopf, PhD, ScD; Karen K. Miller, MD; David M. Nathan, MD; Ross Zafonte, DO; Frank E. Speizer, MD; Theodore K. Courtney, MS; Aaron Baggish, MD; Herman A. Taylor, MD; Alvaro Pascual-Leone, MD, PhD; Lee M. Nadler, MD; Andrea L. Roberts, PhD

**IMPORTANCE** Small studies suggest that head trauma in men may be associated with low testosterone levels and sexual dysfunction through mechanisms that likely include hypopituitarism secondary to ischemic injury and pituitary axonal tract damage. Athletes in contact sports may be at risk for pituitary insufficiencies or erectile dysfunction (ED) because of the high number of head traumas experienced during their careers. Whether multiple symptomatic concussive events are associated with later indicators of low testosterone levels and ED is unknown.

**OBJECTIVE** To explore the associations between concussion symptom history and participant-reported indicators of low testosterone levels and ED.

**DESIGN, SETTING, AND PARTICIPANTS** This cross-sectional study of former professional US-style football players was conducted in Boston, Massachusetts, from January 2015 to March 2017. Surveys on past football exposures, demographic factors, and current health conditions were sent via electronic and postal mail to participants within and outside of the United States. Analyses were conducted in Boston, Massachusetts; the data analysis began in March 2018 and additional analyses were performed through June 2019. Of the 13 720 male former players eligible to enroll who were contacted, 3506 (25.6%) responded.

**EXPOSURES** Concussion symptom score was calculated by summing the frequency with which participants reported 10 symptoms, such as loss of consciousness, disorientation, nausea, memory problems, and dizziness, at the time of football-related head injury.

**MAIN OUTCOMES AND MEASURES** Self-reported recommendations or prescriptions for low testosterone or ED medication served as indicators for testosterone insufficiency and ED.

**RESULTS** In 3409 former players (mean [SD] age, 52.5 [14.1] years), the prevalence of indicators of low testosterone levels and ED was 18.3% and 22.7%, respectively. The odds of reporting low testosterone levels or ED indicators were elevated for previously established risk factors (eg, diabetes, sleep apnea, and mood disorders). Models adjusted for demographic characteristics, football exposures, and current health factors showed a significant monotonically increasing association of concussion symptom score with the odds of reporting the low testosterone indicator (highest vs lowest quartile, odds ratio, 2.39; 95% CI, 1.79-3.19;  $P < .001$ ). The ED indicator showed a similar association (highest quartile vs lowest, odds ratio, 1.72; 95% CI, 1.30-2.27;  $P < .001$ ).

**CONCLUSIONS AND RELEVANCE** Concussion symptoms at the time of injury among former football players were associated with current participant-reported low testosterone levels and ED indicators. These findings suggest that men with a history of head injury may benefit from discussions with their health care clinicians regarding testosterone deficiency and sexual dysfunction.

*JAMA Neurol.* 2019;76(12):1428-1438. doi:10.1001/jamaneurol.2019.2664  
Published online August 26, 2019.

[+ Author Audio Interview](#)

[+ Supplemental content](#)

[+ CME Quiz at  
jamanetwork.com/learning](#)

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Rachel Grashow, PhD, MS, Department of Environmental Health, Harvard T. H. Chan School of Public Health, 655 Huntington Ave, Bldg 1, Ste 1402, Boston, MA 02215 (rgrashow@hsph.harvard.edu).

**H**ealthy sexual function is important for psychosocial well-being<sup>1,2</sup> and intimate partner relations.<sup>3,4</sup> *Erectile dysfunction* (ED), defined as the inability to maintain an erection sufficient for sexual activity,<sup>5</sup> and pituitary hormone deficiencies may be long-term sequelae of traumatic brain injury (TBI).<sup>6</sup> A plausible biological mechanism for such effects is trauma-induced pituitary damage, which may lead to insufficiencies in testosterone, growth hormone, or cortisol levels,<sup>7,8</sup> termed *posttraumatic hypopituitarism*.<sup>9-11</sup>

Studies on sexual function in participants with brain injuries have reported a reduced frequency of intercourse,<sup>10,12-14</sup> diminished libido,<sup>10,12-19</sup> impaired ability to orgasm,<sup>10,12,13,18,19</sup> ED,<sup>6,10,13-15,17</sup> and sexual arousal issues.<sup>10,12,18</sup> However, these studies were conducted in clinical settings,<sup>6,9,10,12-19</sup> many were small (N < 100)<sup>9,13-15,17,19</sup> or did not specifically investigate ED.<sup>12,16,18,19</sup> Only 1 large study examined ED subsequent to a single TBI in 73 000 clinical patients and 218 000 controls.<sup>6</sup> Over a 10-year follow-up, the adjusted hazard ratio for ED in patients with TBI was 2.5 compared with participants without injuries, and greater TBI severity was associated with higher risk of ED.<sup>6</sup> However, this study focused only on medically evaluated single head injuries, rendering results less applicable to often underdiagnosed sports-related head traumas.<sup>20,21</sup> Furthermore, this study did not evaluate dose-response associations with repeated head injuries and lacked covariate data, such as body mass index (BMI; calculated as weight in kilograms divided by height in meters squared).<sup>22</sup>

Limited research has been conducted on populations likely to receive repeated head injuries, such as athletes in combative and contact sports or the military. Small studies of professional boxers have found hormone insufficiencies<sup>23-25</sup> and smaller pituitary volumes<sup>23</sup> when compared with controls. One study of 68 National Football League (NFL) players with poor quality-of-life scores found significant associations between repeated mild head injury and pituitary and sexual dysfunction.<sup>26</sup> Three small studies (all N < 40) reported that veterans with mild blast-related head injury were more likely to have a pituitary hormone insufficiency compared with civilians and uninjured veterans.<sup>27-29</sup> Exploring these end points in professional US-style football players could yield new insights given that prior studies were small, looked only at clinically defined single head injuries, were conducted in players with a low quality of life, or were conducted in veterans with blast-related rather than mechanical trauma.

We examined the association between football-related concussion symptoms at the time of football injury and self-reported medication recommendations for low testosterone levels or ED in a large cohort of former professional US-style football players. Because former players are at increased risk for ED comorbidities, such as sleep apnea,<sup>30,31</sup> cardiometabolic disease,<sup>32-34</sup> opioid use,<sup>35</sup> depression,<sup>30,36-41</sup> obesity,<sup>30</sup> and prior use of performance enhancing drugs,<sup>42</sup> we conducted analyses further adjusted for these factors.

## Methods

### Participants

The Football Players' Health Study (FPHS)<sup>43</sup> recruited men who played for the NFL after 1960, when the adoption of hard plas-

### Key Points

**Question** Are professional US-style football players with a history of multiple concussion symptoms more likely to report indicators of low testosterone levels or erectile dysfunction (ED)?

**Findings** In this cross-sectional study of 3409 former players, a monotonically increasing association was found between the number of concussion symptoms and the odds of reporting an indicator of low testosterone level and ED.

**Meaning** Concussion symptoms among former football players were associated with low testosterone levels and ED indicators, suggesting that men with a history of head injury may benefit from discussions with their health care clinicians regarding these treatable outcomes.

tic helmets was mostly complete. Of the 14 906 player addresses obtained from the NFL Players' Association, 1186 (8.6%) were invalid. Questionnaires were sent to the remaining 13 720 former players, of whom 3506 (25.6%) had responded as of March 2017. The Beth Israel Deaconess Medical Center institutional review board approved this study. Informed written consent was obtained from all participants prior to participation.

### Concussion Symptoms

Respondents were asked: "While playing or practicing football, did you experience a blow to the head, neck, or upper body followed by any of the following: headaches, nausea, dizziness, loss of consciousness (LOC), memory problems, disorientation, confusion, seizure, visual problems, or feeling unsteady on your feet?" Response options were: none, once, 2 to 5 times, 6 to 10 times, or 11 times or more for each symptom.

### Outcomes

Respondents were asked "Has a medical provider ever recommended or prescribed medicine for: (1) low testosterone or (2) ED?" An affirmative answer served as an indicator of a history of low testosterone levels or ED, respectively. Participants reporting that a health care clinician had ever recommended or prescribed medication for either outcome were considered cases. Participants were additionally asked whether they currently took medication for low testosterone levels or ED.

### Covariates

Participants chose the category that best described their race/ethnicity and were categorized by investigators as black, white, or other. Football position may be a proxy for training regimen, nutrition, and other unmeasured variables and has been associated with injuries.<sup>44-47</sup> Respondents provided the position(s) played most frequently, which included defensive back, defensive line, kicker/punter, linebacker, offensive line, quarterback, running back, special teams, tight end, or wide receiver. Respondents who selected "special teams" in addition to strength-based positions (eg, offensive line, defensive line, or tight end) were assigned "special line."<sup>48</sup> Players who selected "special teams" and speed-based positions (eg, running back, wide receiver, defensive back, or linebacker) were assigned to "special speed." For the 1037 players (29.6% of all respondents) who endorsed multiple

positions, we assigned the highest-risk position based on mild TBI risk per 100 game positions.<sup>44</sup>

Body mass index during professional play was calculated using self-reported height and professional weight (<25.0, 25.0-30.0, or >30.0). Participants reported the number of seasons of professional play. For 70 men (2.1%) missing these data, total seasons were calculated using the first and last year of professional play or from Pro-Football Reference (PFR) data.<sup>49</sup> Participants were asked “During your active playing years, did you take any medications or other drugs to help performance?”

Participants were asked whether they had ever been recommended or prescribed medication for hypertension, high cholesterol levels, diabetes, heart failure, heart rhythm issues, and/or pain. They were separately asked if they had received a diagnosis of cancer, sleep apnea, or myocardial infarction or had undergone cardiac surgery. Participants were considered to have a heart condition if they reported heart rhythm issues, myocardial infarction, heart failure, or cardiac surgery. Self-reported weight and height were used to calculate their current BMI.

Anxious and depressive symptoms over the prior 2 weeks were assessed using the Patient Health Questionnaire 4. Responses were separately summed for anxious and depressive symptoms and dichotomized at more than 3 to indicate high depressive or anxiety symptoms.<sup>50,51</sup> Participants were considered to have depression or anxiety if they reported high symptoms or were currently prescribed antidepressants or anxiolytics, respectively. Alcohol intake was quantified as the total number of alcohol beverages consumed per week.

### Statistical Analyses

We calculated the mean age, number of seasons, start year, and end year for study participants. To examine selection bias, we used PFR data to compare the FPHS cohort with all former players who played after 1960. Two-sample *t* tests and  $\chi^2$  tests were used to identify differences between the FPHS and PFR.

Concussion symptom frequency responses of none, once, 2 to 5 times, 6 to 10 times, or 11 or more were coded as 0, 1, 3.5, 8, and 13, respectively, and then summed to create a concussion symptom score. This score was then divided into quartiles to minimize the influence of outliers. Participants who did not respond to more than 5 concussion symptoms were excluded (*n* = 97). Of the 3409 remaining participants, 1 or more missing symptoms were imputed for 365 players (10.7%) via multiple imputation using chained equations.<sup>52</sup> Thirty-nine participants (1.1%) who did not respond to the LOC question were excluded from models examining LOC as the exposure. Data from participants who did not respond to outcome questions were excluded from related analyses (low testosterone levels,  $N_{\text{missing}} = 75$  [2.2%]; ED,  $N_{\text{missing}} = 77$  [2.3%]). Multiple imputation was used for covariates with missing data ( $N_{\text{missing}} = 3$  to 88).

To determine whether indicators of low testosterone levels and ED were more prevalent among men with established low testosterone levels and ED risk factors (eg, diabetes), we examined associations between risk factors and outcomes in age- and race-adjusted models. To measure the association of concussion symptom scores with indicators of low testosterone levels and ED, we calculated odds ratios (ORs) separately for indicators of low testosterone levels and ED as the

dependent variable and concussion symptoms as the independent variable after adjusting for age and race. Models were further adjusted for football exposures and current health factors in exploratory analyses. To address the possibility that recall bias may have affected the number of reported concussion symptoms, we used LOC as a more easily recalled exposure.<sup>53,54</sup> To test for linear trends, the median of the concussion symptom quartile or LOC category was assigned to each participant and entered in models as a continuous variable. We additionally examined concussion scores and LOC as continuous measures. To determine whether current health factors statistically mediated associations between concussion scores and low testosterone levels or ED, we fit fully adjusted models with and without each current health factor. We calculated the percentage mediation for each variable as:  $100 * ((\beta_{\text{without mediator}} - \beta_{\text{with mediator}}) / \beta_{\text{without mediator}})$ .

To increase the likelihood that we were capturing men with low testosterone levels and ED, we separately considered only the subset of men who reported currently taking medication for low testosterone levels or ED as cases, excluding men who reported a history of medication recommendation or prescription but no current use. We next examined associations in younger players by restricting the data set to men 50 years or younger. We also restricted the data set to men who last played 20 years or fewer before the survey to determine whether concussion symptoms experienced 2 or more decades prior were associated with the outcomes. Depression and anxiety can lead to ED,<sup>55-57</sup> and low testosterone levels<sup>58</sup> and ED<sup>59,60</sup> may cause or exacerbate depression. We therefore included indicators of depression and anxiety in sensitivity analyses. To address the possibility that stigma associated with ED was associated with the response rate, we ran analyses in which all ED nonrespondents were imputed as either “no ED” or “have ED.”

We used inverse probability weighting<sup>61</sup> to account for possible selection bias from nonparticipation in the FPHS. We predicted the probability of participation in the FPHS based on position, BMI, career length, and first and last year of professional play using PFR data. The inverse of these probabilities, stabilized and truncated at the 5th and 95th percentiles to minimize the effect of outliers, were used as weights in fully adjusted models of low testosterone levels and ED.<sup>49,61</sup> Odds ratios for all analyses were estimated using generalized linear models (“glm” package; R Statistical Software; R Foundation) and statistical significance was set at  $P < .05$ .

## Results

**Table 1** shows the distribution of demographic, football, and current health-related variables by concussion symptom quartile. Participants’ mean (SD) age was 52.5 (14.1) years. Participants had played a mean (SD) of 6.8 (3.8) seasons. Respondents of the FPHS began their careers 4 years earlier than nonrespondents, ended their careers 3 years earlier, and had slightly longer careers (career start:  $t = 13.1$ ; 95% CI, 3.2-4.4; career end:  $t = 9.3$ ; 95% CI, 2.1-3.2; career duration:  $t = 14.3$ ; 95% CI, -1.3 to -1.0;  $P < .001$  for all). Playing position differed among respondents vs nonrespondents (offensive linemen:

**Table 1. Demographic, Football, and Current Health Factors by Concussion Symptom Quartile for 3409 Participants**

Quartile (Concussion Score Range)	Concussion Symptom Quartile, No. (%)			
	1 (0.0-10.5)	2 (10.5-23.0)	3 (23.5-43.5)	4 (43.5-130.0)
No.	853 (25.0)	852 (25.0)	852 (25.0)	852 (25.0)
<b>Demographic Factors</b>				
Age, y				
21-40	202 (23.7)	198 (23.2)	228 (26.8)	240 (28.2)
41-60	308 (36.1)	341 (40.0)	398 (46.7)	416 (48.8)
>60	343 (40.2)	313 (36.7)	226 (26.5)	196 (23.0)
Race/ethnicity				
Black	310 (36.6)	286 (34.2)	347 (41.2)	331 (39.1)
White	514 (60.8)	534 (63.9)	479 (56.8)	475 (56.1)
Other	22 (2.6)	16 (1.9)	17 (2.0)	40 (4.7)
<b>Football Exposures</b>				
BMI while playing professional football <sup>a</sup>				
<25.0	63 (7.4)	36 (4.2)	49 (5.8)	39 (4.6)
25.0-30.0	427 (50.1)	404 (47.4)	379 (44.5)	322 (37.8)
>30.0	363 (42.6)	412 (48.4)	423 (49.6)	491 (57.6)
Professional use of PED	87 (10.2)	99 (11.6)	135 (15.8)	229 (26.9)
Position				
Defensive back	117 (13.7)	118 (13.8)	142 (16.7)	122 (14.3)
Defensive line	104 (12.2)	83 (9.7)	82 (9.6)	100 (11.7)
Kicker/punter	61 (7.2)	23 (2.7)	14 (1.6)	6 (0.7)
Linebacker	81 (9.5)	79 (9.3)	86 (10.1)	113 (13.3)
Offensive line	137 (16.1)	179 (21.0)	155 (18.2)	157 (18.4)
Quarterback	51 (6.0)	58 (6.8)	36 (4.2)	18 (2.1)
Running back	70 (8.2)	68 (8.0)	87 (10.2)	94 (11.0)
Special teams only	3 (0.4)	10 (1.2)	8 (0.9)	6 (0.7)
Special speed	20 (2.3)	34 (4.0)	43 (5.0)	37 (4.3)
Special strength	36 (4.2)	49 (5.8)	48 (5.6)	56 (6.6)
Tight end	59 (6.9)	64 (7.5)	68 (8.0)	71 (8.3)
Wide receiver	114 (13.4)	87 (10.2)	83 (9.7)	72 (8.5)
Current health-related factors				
Hypertension	322 (37.7)	306 (35.9)	326 (38.3)	329 (38.6)
High cholesterol levels	272 (31.9)	289 (33.9)	309 (36.3)	303 (35.6)
Diabetes	60 (7.0)	92 (10.8)	76 (8.9)	72 (8.5)
Heart condition <sup>b</sup>	160 (18.8)	170 (20.0)	155 (18.2)	152 (17.8)
Prescription pain medication	127 (14.9)	203 (23.8)	280 (32.9)	360 (42.3)
Prostate or testicular cancer	33 (3.9)	42 (4.9)	24 (2.8)	33 (3.9)
Sleep apnea	127 (14.9)	178 (20.9)	198 (23.2)	257 (30.2)
Current BMI <sup>a</sup>				
<25.0	60 (7.0)	46 (5.4)	52 (6.1)	20 (2.3)
25.0-30.0	388 (45.5)	372 (43.7)	337 (39.6)	333 (39.1)
>30.0	401 (47.0)	429 (50.4)	457 (53.6)	494 (58.0)
Mood indicators				
Anxiety only	28 (3.3)	42 (4.9)	68 (8.0)	98 (11.5)
Depression only	17 (2.0)	30 (3.5)	47 (5.5)	45 (5.3)
Depression and anxiety	26 (3.0)	68 (8.0)	113 (13.3)	262 (30.8)
Alcohol drinks per wk				
None	268 (31.4)	270 (31.7)	253 (29.7)	271 (31.8)
1-7	314 (36.8)	329 (38.6)	309 (36.3)	314 (36.9)
8-14	158 (18.5)	146 (17.1)	145 (17.0)	137 (16.1)
≥15	99 (11.6)	101 (11.9)	134 (15.7)	122 (14.3)

Abbreviations: BMI, body mass index; PED, performance-enhancing drugs.

<sup>a</sup> Calculated as weight in kilograms divided by height in meters squared.

<sup>b</sup> Heart condition includes self-reported heart rhythm issues, myocardial infarction, heart failure, or cardiac surgery.

**Table 2. Prevalence of History of Low Testosterone Levels and Erectile Dysfunction Indicators by Demographic, Football, and Current Health Factors for 3409 Participants**

Characteristic	No.	Prevalence of History of Prescription Recommendation by Self-report, No. (%)	
		Low Testosterone Levels	Erectile Dysfunction
All		611 (18.3)	755 (22.7)
<b>Demographic Factors</b>			
Age, y			
21-40	868	70 (8.2)	46 (5.4)
41-60	1463	301 (20.9)	307 (21.4)
>60	1078	240 (23.1)	402 (38.6)
Race			
Black	1274	210 (16.8)	280 (22.5)
White	2002	373 (19.1)	454 (23.2)
Other	95	23 (24.2)	14 (15.2)
Missing	38	5 (13.5)	7 (18.9)
<b>Football Exposures</b>			
BMI while playing professional football <sup>a</sup>			
<25.0	187	33 (17.7)	36 (19.9)
25.0-30.0	1532	243 (16.3)	353 (23.6)
>30.0	1689	334 (20.2)	365 (22.0)
Professional use of PED			
No	2859	471 (16.8)	608 (21.8)
Yes	550	140 (26.1)	147 (27.3)
<b>Current Health-Related Factors</b>			
Hypertension			
No	2083	287 (13.9)	297 (14.5)
Yes	1283	318 (25.5)	450 (35.9)
High cholesterol levels			
No	2165	292 (13.7)	352 (16.5)
Yes	1173	309 (27.0)	387 (33.6)
Diabetes			
No	3021	504 (16.9)	596 (20.0)
Yes	300	95 (32.5)	136 (46.7)
Heart condition <sup>b</sup>			
No	2772	437 (16.0)	522 (19.2)
Yes	637	174 (28.5)	233 (37.8)
Prescription pain medication			
No	2439	328 (13.7)	415 (17.4)
Yes	970	283 (29.9)	340 (35.7)
Prostate or testicular cancer			
No	3277	576 (18)	686 (21.4)
Yes	132	35 (27.1)	69 (54.3)
Sleep apnea			
No	2582	367 (14.5)	478 (18.8)
Yes	760	236 (31.9)	264 (35.7)
Current BMI <sup>a</sup>			
<25.0	178	16 (9.1)	32 (18.4)
25.0-30.0	1430	211 (15.1)	276 (19.8)
>30.0	1781	383 (22.0)	442 (25.4)

(continued)

**Table 2. Prevalence of History of Low Testosterone Levels and Erectile Dysfunction Indicators by Demographic, Football, and Current Health Factors for 3409 Participants (continued)**

Characteristic	No.	Prevalence of History of Prescription Recommendation by Self-report, No. (%)	
		Low Testosterone Levels	Erectile Dysfunction
<b>Mood indicators<sup>c</sup></b>			
No depression or anxiety	2562	357 (14.3)	479 (19.1)
Anxiety only	236	44 (19.0)	49 (21.2)
Depression only	139	36 (26.5)	43 (31.9)
Depression and anxiety	469	174 (37.8)	184 (40)
<b>Alcohol drinks per wk</b>			
None	1062	213 (20.5)	240 (23.1)
1-7	1266	210 (17.0)	266 (21.5)
8-14	586	97 (17.0)	128 (22.1)
≥15	456	85 (19.0)	111 (24.8)

Abbreviations: BMI, body mass index; PED, performance-enhancing drugs.

<sup>a</sup> Calculated as weight in kilograms divided by height in meters squared.

<sup>b</sup> Heart condition includes self-reported heart rhythm issues, myocardial infarction, heart failure, or cardiac surgery.

<sup>c</sup> Derived from Patient Health Questionnaire 4.

FPHS, 21.7%; nonrespondents, 3.6%;  $\chi^2 = 100.9$ ;  $P < .001$ ; defensive backs: FPHS, 14.8%; nonrespondents, 9.9%;  $\chi^2 = 40.7$ ;  $P < .001$ ; running backs: FPHS, 9.4%; nonrespondents, 13.3%;  $\chi^2 = 32.3$ ;  $P < .001$ ; tight ends: FPHS, 7.7%; nonrespondents, 5.9%;  $\chi^2 = 11.7$ ;  $P < .001$ ; wide receivers: FPHS, 0.5%; nonrespondents, 12.4%;  $\chi^2 = 7.9$ ;  $P < .001$ ).

Of 3409 participants, 611 (18.3%) reported indicators of low testosterone levels, and 755 (22.7%) reported indicators of ED. Fewer than 10% of participants reported indicators of low testosterone levels and ED (335 [9.8%]). Of 611 players with low testosterone indicators, 243 (39.8%) were currently taking medication. Among players with indicators of ED, half were currently taking medication (379 [50.2%]). The prevalence of indicators of low testosterone levels and ED was greater in men with established risk factors (Table 2). In models that included age and race, indicators of low testosterone levels and ED were significantly associated with hypertension, high cholesterol levels, diabetes, heart conditions, prescription pain medication, reproductive cancer, sleep apnea, obesity, and mood disorders (Table 3).

We found statistically significant, monotonically increasing associations between concussion symptoms and indicators for low testosterone levels and ED in models adjusted for age and race (Figure; low testosterone OR, 3.49; 95% CI, 2.68-4.56; ED OR, 2.41; 95% CI, 1.87-3.11). In models further adjusted for professional football-related exposures (eg, position, BMI during professional play, and self-reported use of performance enhancing drugs), estimates remained essentially unchanged from age- and race-adjusted models (Figure; low testosterone OR, 3.38; 95% CI, 2.57-4.45; ED OR, 2.32; 95% CI, 1.78-3.02).

Associations in models further adjusted for current health factors were slightly attenuated but remained statistically significant (Figure; low testosterone OR, 2.39; 95% CI, 1.79-3.19;



ED OR, 1.72; 95% CI, 1.30-2.27). Loss of consciousness was associated with indicators of low testosterone levels and ED in models adjusted for demographics, football exposures, and current risk factors (Figure). In fully adjusted models with concussion symptoms and LOC coded as continuous variables, both were significantly associated with low testosterone levels and ED (concussion symptoms: low testosterone  $\beta = 1.01$ ; 95% CI, 1.01-1.02;  $P \leq .001$ ; ED  $\beta = 1.01$ ; 95% CI, 1.01-1.01;  $P \leq .001$ ; LOC: low testosterone  $\beta = 1.08$ ; 95% CI, 1.04-1.12;  $P \leq .001$ ; ED  $\beta = 1.06$ ; 95% CI, 1.02-1.10;  $P = .001$ ). For low testosterone, men with relatively low concussion scores (the second quartile) had significantly elevated ORs compared with men in the lowest quartile (OR, 1.41; 95% CI, 1.05-1.89;  $P = .02$ ).

The largest statistical mediators of the association between concussion score and the outcomes were current use of prescription pain medication (low testosterone mediation, 7.9%; ED mediation, 20.4%) and sleep apnea (low testosterone mediation, 9.7%; ED mediation, 5.9%). All other current health factors statistically mediated the associations by less than 4%.

Results were similar in analyses restricted to participants currently using low testosterone and ED medication among players younger than 50 years, among players who played 20 years or longer before the study, and in inverse probability-weighted analyses. Further adjustment for mood indicators somewhat attenuated associations (Table 4). We conducted a post hoc analysis to compare associations among men with low testosterone levels only, ED only, and men with both. Associations with concussion symptoms were stronger among men reporting low testosterone levels and ED compared with men reporting only 1 of the 2 outcomes (eTable in the Supplement; highest concussion quartile vs lowest; men with low testosterone only: OR, 2.66; 95% CI, 1.84-3.83,  $P < .001$ ; men with ED only: OR, 1.47; 95% CI, 1.06-2.04;  $P = .02$ ; men with both outcomes: OR, 4.95; 95% CI, 3.40-7.22;  $P < .001$ ).

## Discussion

We identified a highly robust, monotonically increasing association between self-reported concussion symptoms at the time of football injury and self-reported low testosterone levels and ED indicators. Even participants with relatively few concussion symptoms (ie, those in the second quartile) had significantly elevated odds of reporting low testosterone levels compared with men in the lowest quartile.

Our findings add to a literature composed of studies linking single head injuries with pituitary dysfunction in the general population,<sup>6,9-11</sup> small studies of professional boxers,<sup>23-26,62,63</sup> and findings from veterans with blast-induced head injury,<sup>27-29</sup> indicating that mechanical and blast-induced trauma may have associations with pituitary and sexual function. To our knowledge, this is the first large study to examine low testosterone levels and ED, albeit indirectly, in a nonclinical population with a high prevalence of repeated injuries. This is also the first study to adjust for risk factors such as BMI.

Several hypothesized mechanisms, including concussion-associated hypopituitarism, may explain the associations of

**Table 3. Low Testosterone Levels or ED Indicators in Association With Established Low Testosterone Levels and ED Risk Factors for 3409 Participants**

Characteristic	Prevalence of History of Prescription Recommendation by Self-report, OR (95% CI)	
	Low Testosterone	ED
<b>Model 1: Mutually Adjusted for Age and Race</b>		
Age, y		
21-40	1 [Reference]	1 [Reference]
41-60	2.99 (2.27-3.94) <sup>a</sup>	4.82 (3.49-6.66) <sup>a</sup>
>60	3.41 (2.56-4.55) <sup>a</sup>	12.22 (8.79-16.98) <sup>a</sup>
Race/ethnicity		
White	1 [Reference]	1 [Reference]
Black	0.97 (0.80-1.17)	1.4 (1.17-1.69) <sup>a</sup>
Other	1.61 (0.98-2.64)	0.87 (0.47-1.59)
Missing	0.64 (0.25-1.67)	0.63 (0.27-1.50)
<b>Models 2-10: Age and Race Adjusted</b>		
Model 2: hypertension	1.81 (1.50-2.19) <sup>a</sup>	2.26 (1.89-2.71) <sup>a</sup>
Model 3: high cholesterol levels	1.96 (1.62-2.37) <sup>a</sup>	1.69 (1.41-2.02) <sup>a</sup>
Model 4: diabetes	2.04 (1.55-2.69) <sup>a</sup>	2.66 (2.04-3.45) <sup>a</sup>
Model 5: heart condition <sup>b</sup>	1.73 (1.39-2.15) <sup>a</sup>	1.64 (1.34-2.01) <sup>a</sup>
Model 6: prescription pain medication	2.53 (2.10-3.05) <sup>a</sup>	2.3 (1.93-2.75) <sup>a</sup>
Model 7: prostate or testicular cancer	1.31 (0.87-1.97)	2.54 (1.75-3.69) <sup>a</sup>
Model 8: sleep apnea	2.51 (2.07-3.05) <sup>a</sup>	2.04 (1.69-2.46) <sup>a</sup>
Model 9: current BMI <sup>c</sup>		
<25.0	1 [Reference]	1 [Reference]
25.0-30.0	1.93 (1.13-3.32) <sup>d</sup>	1.35 (0.88-2.06)
>30.0	3.11 (1.82-5.30) <sup>a</sup>	1.99 (1.31-3.02) <sup>e</sup>
Model 10: mood disorders		
None	1 [Reference]	1 [Reference]
Anxiety indicators only	1.63 (1.14-2.33) <sup>e</sup>	1.59 (1.12-2.26) <sup>d</sup>
Depression indicators only	2.22 (1.48-3.34) <sup>a</sup>	2.11 (1.41-3.15) <sup>a</sup>
Depression and anxiety indicators	4 (3.19-5.02) <sup>a</sup>	3.37 (2.67-4.24) <sup>a</sup>
Model 11: alcohol drinks per wk		
None	1 [Reference]	1 [Reference]
1-7	0.84 (0.68-1.05)	1.03 (0.84-1.27)
8-14	0.81 (0.61-1.06)	0.99 (0.76-1.28)
15+	0.94 (0.71-1.26)	1.27 (0.96-1.67)

Abbreviations: BMI, body mass index; ED, erectile dysfunction; OR, odds ratio.

<sup>a</sup>  $P < .001$ .

<sup>b</sup> Heart condition includes self-reported heart rhythm issues, myocardial infarction, heart failure, or cardiac surgery.


<sup>c</sup> Calculated as weight in kilograms divided by height in meters squared.

<sup>d</sup>  $P < .05$ .

<sup>e</sup>  $P < .01$ .

concussion with low testosterone levels and ED. The pituitary gland is perfused by long portal vessels branching off the internal carotid artery,<sup>64</sup> making it susceptible to mechanical trauma, low cerebral blood flow, and increased intracranial pressure associated with head injury.<sup>65,66</sup> Acceleration and deceleration forces can shear axonal tracts that connect the pituitary to the hypothalamus. Thus, the combination of intracranial pressure, reduced blood flow, and diffuse axonal injury

Figure. Association Between Concussion Symptom Quartile and Loss of Consciousness With Low Testosterone and Erectile Dysfunction



A and B, The lowest quartile served as the reference for all models. The base model is adjusted for age and race/ethnicity; the football exposure model is further adjusted for body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) while playing professional football, position, and use of performance-enhancing drugs; and the fully adjusted model is further adjusted for current BMI, heart condition, diabetes, high cholesterol levels, hypertension, sleep apnea, use of prescription pain medication, alcohol drinks per week, and a history of testicular or prostate cancer. Linear tests of trend were significant ( $P < .01$ ).

between the pituitary and the hypothalamus could cause diminished pituitary function, leading to low testosterone levels and ED. In exploratory mediation analyses, we found that adjusting for current prescription pain medication use and sleep apnea modestly attenuated the association of concussion symptoms with low testosterone levels and ED. These results suggest that pain medication and sleep apnea should be explored as possible pathways through which head injury affects hormone levels and sexual function.

**Limitations**

Our study has several limitations. First, we used indirect measures of low testosterone levels and ED. However, participant-reported health care clinician medication recommendations may be reasonable proxies: self-reported sexual dysfunction single-question assessments<sup>67,68</sup> have largely replaced invasive physiological tests in clinical and research settings.<sup>69-71</sup> Medical records, often a criterion standard for case ascertainment for other outcomes, may be less reliable for sexual dysfunction given that only 30% of men seek medical treatment for ED.<sup>72</sup> Nevertheless, US men are comparatively more likely to seek treatment vs men in European countries (56% vs 10%-47%) and more willing to take ED

medication.<sup>73</sup> Moreover, the validity of our indicators is supported by statistically significant associations with known low testosterone and ED risk factors and by sensitivity analyses in men who self-reported currently using testosterone therapy and ED medication.

Second, concussion data were collected retrospectively, raising the possibility of recall bias. However, the robust monotonic association of the concussion exposure with the outcomes suggests simple recall bias may not solely account for our findings. Third, the concussion symptom scale has not been validated. To our knowledge, there is no validated retrospective measure of concussion symptoms. In our data, findings were similar using LOC count.<sup>53,54,74,75</sup> Moreover, simpler metrics, such as the number of diagnosed concussions, may not adequately capture the experience of concussion or concussion severity; at least 30% of concussions may be undiagnosed,<sup>21,75,76</sup> players may hide concussions,<sup>21</sup> and concussion management during professional play has changed over time.<sup>45</sup> Concussion symptoms have been used previously as a surrogate for head injury exposure and severity.<sup>77-80</sup>

Fourth, we do not know whether low testosterone levels or ED preceded men's exposure to professional football.

**Table 4. Sensitivity Analyses for Low Testosterone Levels and Erectile Dysfunction Indicators for Each Quartile of Concussion Symptom Score for 3409 Participants**

Model	No.		Concussion Symptom Quartile	History of Prescription Recommendation, OR (95%)	
	Low Testosterone Levels	Erectile Dysfunction		Low Testosterone Levels	Erectile Dysfunction
Model 1: base model <sup>a</sup>	3334	3332	1	1 [Reference]	1 [Reference]
			2	1.62 (1.23-2.15) <sup>b</sup>	1.49 (1.15-1.92) <sup>b</sup>
			3	1.97 (1.49-2.6) <sup>c</sup>	1.96 (1.53-2.53) <sup>c</sup>
			4	3.49 (2.68-4.56) <sup>c</sup>	2.41 (1.87-3.11) <sup>c</sup>
Model 2: case definition includes only current medication users <sup>a</sup>	3334	3332	1	1 [Reference]	1 [Reference]
			2	1.67 (1.10-2.56) <sup>d</sup>	1.21 (0.88-1.67)
			3	1.93 (1.26-2.94) <sup>b</sup>	1.65 (1.21-2.24) <sup>b</sup>
			4	3.02 (2.02-4.5) <sup>c</sup>	1.62 (1.18-2.24) <sup>b</sup>
Model 3: restricted to men ≤50 y <sup>a</sup>	1460	1457	1	1 [Reference]	1 [Reference]
			2	1.41 (0.84-2.38)	1.69 (0.90-3.18)
			3	1.72 (1.05-2.83) <sup>d</sup>	2.75 (1.53-4.93) <sup>b</sup>
			4	2.92 (1.83-4.66) <sup>c</sup>	3.29 (1.85-5.85) <sup>c</sup>
Model 4: men who last played ≥20 y prior <sup>a</sup>	1953	1953	1	1 [Reference]	1 [Reference]
			2	1.57 (1.14-2.17) <sup>b</sup>	1.48 (1.12-1.95) <sup>b</sup>
			3	1.76 (1.27-2.44) <sup>b</sup>	1.79 (1.35-2.38) <sup>c</sup>
			4	3.08 (2.24-4.24) <sup>c</sup>	2.09 (1.56-2.80) <sup>c</sup>
Model 5: fully adjusted including mood disorders <sup>e</sup>	3334	3332	1	1 [Reference]	1 [Reference]
			2	1.33 (0.99-1.78)	1.19 (0.91-1.56)
			3	1.41 (1.05-1.90) <sup>d</sup>	1.43 (1.09-1.88) <sup>d</sup>
			4	1.89 (1.39-2.55) <sup>c</sup>	1.36 (1.02-1.83) <sup>d</sup>
Model 6: missing imputed as no <sup>a</sup>	3409	3409	1	1 [Reference]	1 [Reference]
			2	1.61 (1.22-2.13) <sup>b</sup>	1.48 (1.15-1.91) <sup>b</sup>
			3	1.91 (1.45-2.52) <sup>c</sup>	1.96 (1.52-2.52) <sup>c</sup>
			4	3.43 (2.63-4.48) <sup>c</sup>	2.34 (1.82-3.02) <sup>c</sup>
Model 7: missing imputed as yes <sup>a</sup>	3409	3409	1	1 [Reference]	1 [Reference]
			2	1.67 (1.29-2.17) <sup>c</sup>	1.51 (1.18-1.92) <sup>b</sup>
			3	2 (1.54-2.60) <sup>c</sup>	1.93 (1.52-2.46) <sup>c</sup>
			4	3.37 (2.61-4.34) <sup>c</sup>	2.46 (1.92-3.14) <sup>c</sup>
Model 8: inverse probability weighted <sup>e</sup>	3334	3332	1	1 [Reference]	1 [Reference]
			2	1.40 (1.04-1.89) <sup>d</sup>	1.34 (1.01-1.77) <sup>d</sup>
			3	1.50 (1.11-2.03) <sup>b</sup>	1.65 (1.25-2.19) <sup>c</sup>
			4	2.44 (1.82-3.29) <sup>c</sup>	1.90 (1.43-2.54) <sup>c</sup>

Abbreviation: OR, odds ratio.

<sup>a</sup> Adjusted for age and race.<sup>b</sup>  $P < .01$ .<sup>c</sup>  $P < .001$ .<sup>d</sup>  $P < .05$ .<sup>e</sup> Adjusted for age, race, professional body mass index (calculated as weight in kilograms divided by height in meters squared), position, use of performance-enhancing drugs, current body mass index, heart condition (eg, heart rhythm issues, myocardial infarction, heart failure, or cardiac surgery), diabetes, high cholesterol levels, hypertension, sleep apnea, alcohol beverages per week, use of prescription pain medication, and history of testicular or prostate cancer.

Fifth, the stigma surrounding sexual dysfunction could affect participants' likelihood of speaking to their health care clinician or responding honestly on the survey.<sup>81</sup> However, this would only produce the results presented in this article if such under-reporting were less likely among men with more reported concussion symptoms. Sixth, bias from the relatively low participation rate could have affected our estimates,<sup>82</sup> although statistically significant monotonic relationships persisted in inverse probability of participation-weighted analyses. Seventh, illicit drug use may affect low testosterone<sup>83,84</sup> and ED<sup>85</sup>; however, we did not query illicit drug use. Finally, health status may have been associated with players' decisions to participate: the healthiest players may have been less motivated to participate and the players with the most impairment may have been unable to participate.<sup>82</sup> However, measures of association would be biased only if participation was concurrently

associated with the exposure (concussion symptoms) and the outcome (low testosterone levels or ED).<sup>86</sup>

## Conclusions

This study's data suggest that concussion symptoms experienced during playing years may place NFL players at risk of low testosterone levels and ED decades later. These findings have implications for civilians and veterans who have experienced head injury, as well as for participants in combative and contact sports (eg, mixed martial arts, hockey, boxing, and soccer) who may experience repeated head trauma. Replication of our findings among nonprofessional football players and in the general population is a critical next step. Treatments for testosterone insufficiency and ED, including testosterone replacement therapy and phosphodiesterase type 5 inhibitors,



are generally considered safe and have high efficacy rates.<sup>87-89</sup> Our results could encourage clinicians to proactively query these treatable outcomes in patients with brain injuries as well

as motivate future longitudinal studies to increase our understanding of the causal association between concussion and low testosterone levels and ED.

#### ARTICLE INFORMATION

**Accepted for Publication:** June 21, 2019.

**Published Online:** August 26, 2019.  
doi:10.1001/jamaneurol.2019.2664

**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](#). © 2019 Grashow R et al. *JAMA Neurology*.

**Author Affiliations:** Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts (Grashow, Weisskopf, Speizer, Courtney, Roberts); Football Players Health Study, Harvard Medical School, Boston, Massachusetts (Grashow, Weisskopf, Miller, Nathan, Zafonte, Speizer, Courtney, Baggish, Taylor, Pascual-Leone, Nadler); Environmental and Occupational Medicine and Epidemiology Program, Harvard T. H. Chan School of Public Health, Boston, Massachusetts (Weisskopf, Courtney); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Miller); Harvard Medical School, Boston, Massachusetts (Miller); Massachusetts General Hospital Diabetes Center, Boston (Nathan); Department of Medicine, Harvard Medical School, Boston, Massachusetts (Nathan); Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Boston, Massachusetts (Zafonte); Massachusetts General Hospital, Harvard Medical School, Boston (Zafonte); Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Zafonte); Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Speizer); Cardiovascular Performance Program, Massachusetts General Hospital, Boston (Baggish); Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, Georgia (Taylor); Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (Pascual-Leone); Dana Farber Cancer Institute, Boston, Massachusetts (Nadler).

**Author Contributions:** Dr Grashow had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Grashow, Weisskopf, Miller, Nathan, Zafonte, Speizer, Pascal-Leone, Roberts.  
**Acquisition, analysis, or interpretation of data:** Grashow, Weisskopf, Miller, Zafonte, Speizer, Courtney, Baggish, Taylor, Pascal-Leone, Nadler, Roberts.

**Drafting of the manuscript:** Grashow, Miller, Zafonte, Baggish, Roberts.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Grashow, Weisskopf, Roberts.  
**Obtained funding:** Zafonte, Courtney, Taylor, Pascal-Leone.

**Administrative, technical, or material support:** Grashow, Nathan, Courtney, Taylor, Pascal-Leone.  
**Supervision:** Weisskopf, Miller, Nathan, Zafonte, Baggish, Pascal-Leone, Nadler, Roberts.

**Other - design of data collection instruments and supervision of data acquisition:** Speizer.

**Conflict of Interest Disclosures:** Drs Grashow, Miller, and Roberts reported grants from the NFL Players Association (NFLPA) during the conduct of the study. Dr Weisskopf reported grants from the NFLPA during the conduct of the study and personal fees from Partners Health Care. Dr Zafonte reported receiving royalties from Oakstone and Demos (serving as coeditor of the text *Brain Injury Medicine*) and serves on the scientific advisory boards of Oxeia Biopharma, Biodirection, EIMINDA, and Myomo. He was partially supported by grants from the National Institute on Disability, Independent Living, and Rehabilitation Research (90DPO039-03-00, 90SI5007-02-04, 90DPO060); US Army Medical Research & Development Command (W81XWH-112-0210); the National Institutes of Health (4 U01NS086090-04, 5R24HD082302-02, and 5U01NS091951-03), and the Football Players Health Study at Harvard University, which is funded by the NFLPA. Dr Zafonte also evaluates patients for the MGH Brain and Body TRUST center sponsored in part by the NFLPA and serves on the Mackey White health committee. Dr Courtney reported grant support from the NFLPA and the Football Players Health Study at Harvard University, which was in turn sponsored by the NFLPA during the development, submission and revision of the manuscript. Dr Baggish reported receiving funding from the National Institutes of Health/National Heart, Lung, and Blood Institute, the NFLPA, the American Heart Association, the American Society of Echocardiography, and the US Department of Defense. He serves as an associate editor for *Medicine Science in Sports & Exercise* and is on the editorial board for *Circulation*. He receives compensation for his role as team cardiologist from US Soccer, US Rowing, the New England Patriots, the Boston Bruins, the New England Revolution, and Harvard University. Dr Pascal-Leone reported personal fees from Neosync, Neuroelectrics, Starlab, Constant Therapy, and Cognito outside the submitted work. He serves as associate editor for *Annals of Neurology*. No other disclosures were reported.

**Funding/Support:** This study was partly supported by the Sidney R. Baer Jr Foundation, the National Institutes of Health (grants R01MH100186, R21AG051846, R01MH111875, R01MH115949, R01 MH117063, R24AG06142, and P01 AG031720), the National Science Foundation, DARPA, the Football Players Health Study at Harvard University, and Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Studies National Institutes of Health grant UL1 RRO25758; Dr Pascual Leone) as well as the NFLPA.

**Role of the Funder/Sponsor:** The NFLPA had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** All of the information and materials in this manuscript are original.

**Additional Contributions:** We thank the study participants, advisors, and staff of the Football Players Health Study. The staff received compensation for their contributions.

#### REFERENCES

- McCabe MP, Althof SE. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex? *J Sex Med*. 2014;11(2):347-363. doi:10.1111/jsm.12374
- Rowland DL. Psychological impact of premature ejaculation and barriers to its recognition and treatment. *Curr Med Res Opin*. 2011;27(8):1509-1518. doi:10.1185/03007995.2011.590968
- Carroll JL, Bagley DH. Evaluation of sexual satisfaction in partners of men experiencing erectile failure. *J Sex Marital Ther*. 1990;16(2):70-78. doi:10.1080/00926239008405253
- McCabe MP. Relationship factors in the development and maintenance of ED: implications for treatment effectiveness. *J Sex Med*. 2008;5(8):1795-1804. doi:10.1111/j.1743-6109.2008.00878.x
- Montorsi F, Adaihan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. *J Sex Med*. 2010;7(11):3572-3588. doi:10.1111/j.1743-6109.2010.02062.x
- Yang YJ, Chien WC, Chung CH, et al. Risk of erectile dysfunction after traumatic brain injury: a nationwide population-based cohort study in Taiwan. *Am J Mens Health*. 2018;12(4):913-925. doi:10.1177/1557988317750970
- Klose M, Jonsson B, Abs R, et al. From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum—a KIMS analysis. *Eur J Endocrinol*. 2009;161(suppl 1):S75-S83. doi:10.1530/EJE-09-0328
- Scranton RA, Baskin DS. Impaired pituitary axes following traumatic brain injury. *J Clin Med*. 2015;4(7):1463-1479. doi:10.3390/jcm4071463
- Simpson GK, McCann B, Lowy M. Treating male sexual dysfunction after traumatic brain injury: two case reports. *NeuroRehabilitation*. 2016;38(3):281-289. doi:10.3233/NRE-161319
- Hibbard MR, Gordon WA, Flanagan S, Haddad L, Labinsky E. Sexual dysfunction after traumatic brain injury. *NeuroRehabilitation*. 2000;15(2):107-120.
- Sander AM, Maestas KL, Nick TG, et al. Predictors of sexual functioning and satisfaction 1 year following traumatic brain injury: a TBI model systems multicenter study. *J Head Trauma Rehabil*. 2013;28(3):186-194. doi:10.1097/HTR.0b013e31828b4f91
- Ponsford J. Sexual changes associated with traumatic brain injury. *Neuropsychol Rehabil*. 2003;13(1-2):275-289. doi:10.1080/09602010244000363
- Kreuter M, Dahllöf AG, Gudjonsson G, Sullivan M, Siösteen A. Sexual adjustment and its predictors after traumatic brain injury. *Brain Inj*. 1998;12(5):349-368. doi:10.1080/026990598122494

14. Kreutzer JS, Zasler ND. Psychosexual consequences of traumatic brain injury: methodology and preliminary findings. *Brain Inj*. 1989;3(2):177-186. doi:10.3109/02699058909004550
15. Kosteljanetz M, Jensen TS, Nørgård B, Lunde I, Jensen PB, Johnsen SG. Sexual and hypothalamic dysfunction in the postconcussional syndrome. *Acta Neurol Scand*. 1981;63(3):169-180. doi:10.1111/j.1600-0404.1981.tb00769.x
16. Downing MG, Stolwyk R, Ponsford JL. Sexual changes in individuals with traumatic brain injury: a control comparison. *J Head Trauma Rehabil*. 2013;28(3):171-178. doi:10.1097/HTR.0b013e31828b4f63
17. War FA, Jamuna R, Arivazhagan A. Cognitive and sexual functions in patients with traumatic brain injury. *Asian J Neurosurg*. 2014;9(1):29-32. doi:10.4103/1793-5482.131061
18. Sander AM, Maestas KL, Pappadis MR, Sherer M, Hammond FM, Hanks R; NIDRR Traumatic Brain Injury Model Systems Module Project on Sexuality After TBI. Sexual functioning 1 year after traumatic brain injury: findings from a prospective traumatic brain injury model systems collaborative study. *Arch Phys Med Rehabil*. 2012;93(8):1331-1337. doi:10.1016/j.apmr.2012.03.037
19. Sandel ME, Williams KS, Dellapietra L, Derogatis LR. Sexual functioning following traumatic brain injury. *Brain Inj*. 1996;10(10):719-728. doi:10.1080/026990596123981
20. Hobbs JG, Young JS, Bailes JE. Sports-related concussions: diagnosis, complications, and current management strategies. *Neurosurg Focus*. 2016;40(4):E5. doi:10.3171/2016.FOCUS15617
21. Kerr ZY, Mihalik JP, Guskiewicz KM, Rosamond WD, Evenson KR, Marshall SW. Agreement between athlete-recalled and clinically documented concussion histories in former collegiate athletes. *Am J Sports Med*. 2015;43(3):606-613. doi:10.1177/0363546514562180
22. Silva PP, Bhatnagar S, Herman SD, et al. Predictors of hypopituitarism in patients with traumatic brain injury. *J Neurotrauma*. 2015;32(22):1789-1795. doi:10.1089/neu.2015.3998
23. Tanriverdi F, Unluhizarci K, Kocyigit I, et al. Brief communication: pituitary volume and function in competing and retired male boxers. *Ann Intern Med*. 2008;148(11):827-831. doi:10.7326/0003-4819-148-11-200806030-00005
24. Kelestimur F, Tanriverdi F, Atmaca H, Unluhizarci K, Selcuklu A, Casanueva FF. Boxing as a sport activity associated with isolated GH deficiency. *J Endocrinol Invest*. 2004;27(11):RC28-RC32. doi:10.1007/BF03345299
25. Tanriverdi F, De Bellis A, Battaglia M, et al. Investigation of antihypothalamus and antipituitary antibodies in amateur boxers: is chronic repetitive head trauma-induced pituitary dysfunction associated with autoimmunity? *Eur J Endocrinol*. 2010;162(5):861-867. doi:10.1530/EJE-09-1024
26. Kelly DF, Chaloner C, Evans D, et al. Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study. *J Neurotrauma*. 2014;31(13):1161-1171. doi:10.1089/neu.2013.3212
27. Wilkinson CW, Pagulayan KF, Petrie EC, et al. High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury. *Front Neurol*. 2012;3:11. doi:10.3389/fneur.2012.00011
28. Baxter D, Sharp DJ, Feeney C, et al. Pituitary dysfunction after blast traumatic brain injury: the UK BIOSAP study. *Ann Neurol*. 2013;74(4):527-536. doi:10.1002/ana.23958
29. Undurti A, Colasurdo EA, Sikkema CL, et al. Chronic hypopituitarism associated with increased postconcussive symptoms is prevalent after blast-induced mild traumatic brain injury. *Front Neurol*. 2018;9:72. doi:10.3389/fneur.2018.00072
30. Albuquerque FN, Kuniyoshi FH, Calvin AD, et al. Sleep-disordered breathing, hypertension, and obesity in retired National Football League players. *J Am Coll Cardiol*. 2010;56(17):1432-1433. doi:10.1016/j.jacc.2010.03.099
31. Luyster FS, Dunn RE, Lauderdale DS, et al. Sleep-apnea risk and subclinical atherosclerosis in early-middle-aged retired National Football League players. *Nat Sci Sleep*. 2017;9:31-38. doi:10.2147/NSS.S125228
32. Baron SL, Hein MJ, Lehman E, Gersic CM. Body mass index, playing position, race, and the cardiovascular mortality of retired professional football players. *Am J Cardiol*. 2012;109(6):889-896. doi:10.1016/j.amjcard.2011.10.050
33. Tucker AM, Vogel RA, Lincoln AE, et al. Prevalence of cardiovascular disease risk factors among National Football League players. *JAMA*. 2009;301(20):2111-2119. doi:10.1001/jama.2009.716
34. Trexler ET, Smith-Ryan AE, Defreese JD, Marshall SW, Guskiewicz KM, Kerr ZY. Associations between BMI change and cardiometabolic risk in retired football players. *Med Sci Sports Exerc*. 2018;50(4):684-690. doi:10.1249/MSS.0000000000001492
35. Cottler LB, Ben Abdallah A, Cummings SM, Barr J, Banks R, Forchheimer R. Injury, pain, and prescription opioid use among former National Football League (NFL) players. *Drug Alcohol Depend*. 2011;116(1-3):188-194. doi:10.1016/j.drugalcdep.2010.12.003
36. Guskiewicz KM, Marshall SW, Bailes J, et al. Recurrent concussion and risk of depression in retired professional football players. *Med Sci Sports Exerc*. 2007;39(6):903-909. doi:10.1249/mss.0b013e3180383da5
37. Schwenk TL, Gorenflo DW, Dopp RR, Hipple E. Depression and pain in retired professional football players. *Med Sci Sports Exerc*. 2007;39(4):599-605. doi:10.1249/mss.0b013e31802fa679
38. Webner D, Iverson GL. Suicide in professional American football players in the past 95 years. *Brain Inj*. 2016;30(13-14):1718-1721. doi:10.1080/02699052.2016.1202451
39. Allen TW, Vogel RA, Lincoln AE, Dunn RE, Tucker AM. Body size, body composition, and cardiovascular disease risk factors in NFL players. *Phys Sportsmed*. 2010;38(1):21-27. doi:10.3810/psm.2010.04.1758
40. Camilo J, Helzberg JH. Obesity and metabolic syndrome in football players. *Can J Diabetes*. 2011;35(5):486-487. doi:10.1016/S1499-2671(11)80002-X
41. Churchill TW, Krishnan S, Weisskopf M, et al. Weight gain and health affliction among former National Football League players. *Am J Med*. 2018;131(12):1491-1498. doi:10.1016/j.amjmed.2018.07.042
42. Horn S, Gregory P, Guskiewicz KM. Self-reported anabolic-androgenic steroids use and musculoskeletal injuries: findings from the center for the study of retired athletes health survey of retired NFL players. *Am J Phys Med Rehabil*. 2009;88(3):192-200. doi:10.1097/PHM.0b013e318198b622
43. Zafonte R, Pascual-Leone A, Baggish A, et al. The Football Players' Health Study at Harvard University: design and objectives. *Am J Ind Med*. 2019;62(8):643-654. doi:10.1002/ajim.22991
44. Pellman EJ, Powell JW, Viano DC, et al. Concussion in professional football: epidemiological features of game injuries and review of the literature--part 3. *Neurosurgery*. 2004;54(1):81-94. doi:10.1227/01.NEU.0000097267.54786.54
45. Casson IR, Viano DC, Powell JW, Pellman EJ. Twelve years of national football league concussion data. *Sports Health*. 2010;2(6):471-483. doi:10.1177/1941738110383963
46. Chambers CC, Lynch TS, Gibbs DB, et al. Superior labrum anterior-posterior tears in the National Football League. *Am J Sports Med*. 2017;45(1):167-172. doi:10.1177/0363546516673350
47. Dodson CC, Secrist ES, Bhat SB, Woods DP, Deluca PF. Anterior cruciate ligament injuries in National Football League athletes from 2010 to 2013: a descriptive epidemiology study. *Orthop J Sports Med*. 2016;4(3):2325967116631949. doi:10.1177/2325967116631949
48. Lehman EJ. Epidemiology of neurodegeneration in American-style professional football players. *Alzheimers Res Ther*. 2013;5(4):34. doi:10.1186/alzrt188
49. Pro-Football-Reference. Sports reference. <https://www.pro-football-reference.com/>. Accessed August 15, 2014.
50. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. *Gen Hosp Psychiatry*. 2016;39:24-31. doi:10.1016/j.genhosppsych.2015.11.005
51. Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. *Psychosomatics*. 2009;50(6):613-621.
52. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ*. 2009;338:b2393. doi:10.1136/bmj.b2393
53. Barnes DE, Byers AL, Gardner RC, Seal KH, Boscardin WJ, Yaffe K. Association of mild traumatic brain injury with and without loss of consciousness with dementia in US military veterans. *JAMA Neurol*. 2018;75(9):1055-1061. doi:10.1001/jamaneurol.2018.0815
54. Luis CA, Vanderploeg RD, Curtiss G. Predictors of postconcussion symptom complex in community dwelling male veterans. *J Int Neuropsychol Soc*. 2003;9(7):1001-1015. doi:10.1017/S1355617703970044
55. Singh R, Mason S, Lecky F, Dawson J. Prevalence of depression after TBI in a prospective cohort: the SHEFBIT study. *Brain Inj*. 2018;32(1):84-90. doi:10.1080/02699052.2017.1376756
56. Broshek DK, De Marco AP, Freeman JR. A review of post-concussion syndrome and psychological factors associated with concussion.

- Brain Inj.* 2015;29(2):228-237. doi:10.3109/02699052.2014.974674
57. Fann JR, Burlington B, Leonetti A, Jaffe K, Katon WJ, Thompson RS. Psychiatric illness following traumatic brain injury in an adult health maintenance organization population. *Arch Gen Psychiatry.* 2004;61(1):53-61. doi:10.1001/archpsyc.61.1.53
58. Westley CJ, Amdur RL, Irwig MS. High rates of depression and depressive symptoms among men referred for borderline testosterone levels. *J Sex Med.* 2015;12(8):1753-1760. doi:10.1111/jsm.12937
59. Shiri R, Koskimäki J, Tammela TL, Häkkinen J, Auvinen A, Hakama M. Bidirectional relationship between depression and erectile dysfunction. *J Urol.* 2007;177(2):669-673. doi:10.1016/j.juro.2006.09.030
60. Seidman SN, Roose SP. The relationship between depression and erectile dysfunction. *Curr Psychiatry Rep.* 2000;2(3):201-205. doi:10.1007/s11920-996-0008-0
61. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. *Am J Epidemiol.* 2008;168(6):656-664. doi:10.1093/aje/kwn164
62. Tanriverdi F, De Bellis A, Bizzarro A, et al. Antipituitary antibodies after traumatic brain injury: is head trauma-induced pituitary dysfunction associated with autoimmunity? *Eur J Endocrinol.* 2008;159(1):7-13. doi:10.1530/EJE-08-0050
63. Tanriverdi F, Unluhizarci K, Karaca Z, Casanueva FF, Kelestimur F. Hypopituitarism due to sports related head trauma and the effects of growth hormone replacement in retired amateur boxers. *Pituitary.* 2010;13(2):111-114. doi:10.1007/s11102-009-0204-0
64. Hohl A, Mazzuco TL, Coral MH, Schwarzbald M, Walz R. Hypogonadism after traumatic brain injury. *Arch Bras Endocrinol Metabol.* 2009;53(8):908-914. doi:10.1590/S0004-27302009000800003
65. Sundaram NK, Geer EB, Greenwald BD. The impact of traumatic brain injury on pituitary function. *Endocrinol Metab Clin North Am.* 2013;42(3):565-583. doi:10.1016/j.ecl.2013.05.003
66. Tanriverdi F, Schneider HJ, Aimaretti G, Masel BE, Casanueva FF, Kelestimur F. Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. *Endocr Rev.* 2015;36(3):305-342. doi:10.1210/er.2014-1065
67. O'Donnell AB, Araujo AB, Goldstein I, McKinlay JB. The validity of a single-question self-report of erectile dysfunction: results from the Massachusetts Male Aging Study. *J Gen Intern Med.* 2005;20(6):515-519. doi:10.1111/j.1525-1497.2005.0076.x
68. Derby CA, Araujo AB, Johannes CB, Feldman HA, McKinlay JB. Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study. *Int J Impot Res.* 2000;12(4):197-204. doi:10.1038/sj.ijir.3900542
69. Lehmann K, Eichlisberger R, Gasser TC. Lack of diagnostic tools to prove erectile dysfunction: consequences for reimbursement? *J Urol.* 2000;163(1):91-94. doi:10.1016/S0022-5347(05)67980-3
70. Conte HR. Development and use of self-report techniques for assessing sexual functioning: a review and critique. *Arch Sex Behav.* 1983;12(6):555-576. doi:10.1007/BF01542217
71. Cappelleri JC, Siegel RL, Glasser DB, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile dysfunction and the sexual health inventory for men. *Clin Ther.* 2001;23(10):1707-1719. doi:10.1016/S0149-2918(01)80138-7
72. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. *Int J Impot Res.* 2003;15(1):63-71. doi:10.1038/sj.ijir.3900949
73. Shabsigh R, Perelman MA, Laumann EO, Lockhart DC. Drivers and barriers to seeking treatment for erectile dysfunction: a comparison of six countries. *BJU Int.* 2004;94(7):1055-1065. doi:10.1111/j.1464-410X.2004.05104.x
74. Didehban N, Wilmoth K, Fields L, et al. Reliability of self-reported concussion history in retired NFL players. *Annals of Sports Medicine and Research.* 2017;4(3):1115. [https://www.researchgate.net/publication/326020485\\_Reliability\\_of\\_Self-Reported\\_Concussion\\_History\\_in\\_Retired\\_NFL\\_Players](https://www.researchgate.net/publication/326020485_Reliability_of_Self-Reported_Concussion_History_in_Retired_NFL_Players). Accessed January 16, 2018.
75. Meehan WP III, Mannix RC, O'Brien MJ, Collins MW. The prevalence of undiagnosed concussions in athletes. *Clin J Sport Med.* 2013;23(5):339-342. doi:10.1097/JSM.0b013e318291d3b3
76. LaBotz M, Martin MR, Kimura IF, Hetzler RK, Nichols AW. A comparison of a preparticipation evaluation history form and a symptom-based concussion survey in the identification of previous head injury in collegiate athletes. *Clin J Sport Med.* 2005;15(2):73-78. doi:10.1097/01.jsm.0000157649.99867.fc
77. Chen JK, Johnston KM, Collie A, McCrory P, Pfitz A. A validation of the post concussion symptom scale in the assessment of complex concussion using cognitive testing and functional MRI. *J Neuro Neurosurg Psychiatry.* 2007;78(11):1231-1238. doi:10.1136/jnnp.2006.110395
78. Randolph C, Millis S, Barr WB, et al. Concussion symptom inventory: an empirically derived scale for monitoring resolution of symptoms following sport-related concussion. *Arch Clin Neuropsychol.* 2009;24(3):219-229. doi:10.1093/arclin/acp025
79. Henry LC, Tremblay S, Boulanger Y, Ellemberg D, Lassonde M. Neurometabolic changes in the acute phase after sports concussions correlate with symptom severity. *J Neurotrauma.* 2010;27(1):65-76. doi:10.1089/neu.2009.0962
80. Erlanger D, Kaushik T, Cantu R, et al. Symptom-based assessment of the severity of a concussion. *J Neurosurg.* 2003;98(3):477-484. doi:10.3171/jns.2003.98.3.0477
81. Sotomayor M. The burden of premature ejaculation: the patient's perspective. *J Sex Med.* 2005;2(suppl 2):110-114. doi:10.1111/j.1743-6109.2005.20371.x
82. Grashow RG, Roberts AL, Zafonte R, et al. Defining exposures in professional football: professional American-style football players as an occupational cohort. *Orthop J Sports Med.* 2019;7(2):2325967119829212. doi:10.1177/2325967119829212
83. Brown TT, Wisniewski AB, Dobs AS. Gonadal and adrenal abnormalities in drug users: cause or consequence of drug use behavior and poor health outcomes. *Am J Infect Dis.* 2006;2(3):130-135. doi:10.3844/ajidsp.2006.130.135
84. Fronczak CM, Kim ED, Barqawi AB. The insults of illicit drug use on male fertility. *J Androl.* 2012;33(4):515-528. doi:10.2164/jandrol.110.011874
85. Johnson SD, Phelps DL, Cottler LB. The association of sexual dysfunction and substance use among a community epidemiological sample. *Arch Sex Behav.* 2004;33(1):55-63. doi:10.1023/B:ASEB.0000007462.97961.5a
86. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. *Epidemiology.* 2004;15(5):615-625. doi:10.1097/01.ede.0000135174.63482.43
87. Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. *Eur Urol.* 2013;63(5):902-912. doi:10.1016/j.euro.2013.01.012
88. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? *Drugs.* 2005;65(12):1621-1650. doi:10.2165/00003495-200565120-00003
89. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. *Ther Clin Risk Manag.* 2009;5(3):427-448.